TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for Hard-to-Treat lymphoma: experimental drug tegavivint enters human testing
Disease control Recruiting nowThis early-stage trial is testing a drug called tegavivint in about 18 adults whose large B-cell lymphoma has returned or stopped responding to standard treatments. The main goals are to find the safest dose and check for side effects. Tegavivint works by blocking certain protein…
Matched conditions: TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Lapo Alinari • Aim: Disease control
Last updated May 26, 2026 09:02 UTC
-
New Three-Drug cocktail aims to tackle tough lymphoma
Disease control Recruiting nowThis early-phase trial tests a combination of three drugs (mosunetuzumab, polatuzumab vedotin, and lenalidomide) in about 30 adults with diffuse large B-cell lymphoma that has come back or not responded to prior therapy. The main goal is to find the safest dose and see if the com…
Matched conditions: TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:01 UTC